/ BIOPHARMA COMPANY / ACQUIRED BY ROCHE (SIX: RO, ROG; OTCQX: RHHBY) IN 2022
Good Therapeutics, founded in 2016 by molecular biologist John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained their platform and the ability to mine it for innovative drugs to fight cancer and other diseases. The potential for conditionally active protein technology is vast and could be game-changing for patients. Here’s a peek at how Good’s acquisition played out and what the future may hold for its spinout, Bonum Therapeutics.